The challenges faced by pharmaceutical companies are dynamic and evolve with time. Those who have been in the industry for more than 15 years would agree that the questions that pharma used to face were totally different to the problems faced now. While we used to work towards optimising the opportunity for a pharmaceutical product with the highest potential price, reimbursement and access, the objectives have now changed. The scenarios that we face currently can be bucketed into multiple scenarios.

· Launched 12+ years ago : Finding ways to retain brand value after generic and biosimilar entry

· Launched 8-10 years ago: Preparing for generic and biosimilar entry

· Launched 5-6 years ago: Launching in third wave of countries, price competition, brand value proposition

· Launched 2-3 years ago: Launching in second wave of countries, value communication through additional data impacts on price and value with multiple indication launches

· Launch and future preparation: All of the above and launch price optimisation and sequencing, with an additional challenge that the new products are entering a space which is already crowded with established products and unmet need only in specific populations.


If we summarise the above, most products have the challenge of generics and biosimilars entry and/or competition with others to optimise price and access in multiple indications. Multiple indication launches are common not only in oncology, but also immunology and CNS diseases. With high pressure on budgets, achieving a high price and broad reimbursement can seem like a pipe-dream. However, along with these challenges there are new opportunities of market expansion in new countries such as China, Taiwan and others.


To assess multiple indications, the value of the product is directly proportional to unmet needs in treatment, disease severity, number of patients which infers budget impact, and most importantly its clinical magnitude against current and future competitors. Since differentiation on these aspects vary by the target disease, the current and future treatments and product efficacy, the relative value of the product in different diseases needs to be assessed systematically. The Access Infinity team believes that the challenges of assessing multiple indications is not a unique situation, and to find directional solutions, we have created a tool designed to simplify the process - SMART Match. There is high value in learning from these through analogue analysis using SMART Match. A broad approach with every EMA product listed with its indications helps us to sort them and identify benchmarks for our studies. In addition, mapping time difference between launches, target age demographics, sequence of adult and paediatric population further helps in scenario building. SMART Match ensures the creation of strong hypotheses, providing realistic estimates and country specific strategies for products in multiple indication launches.


If you would like to learn more about this innovative and industry-first tool, please download our brochure here.


Dr. Shrinivas Rao Mukku

Founding Director,

Access Infinity

London, UK




  • ahmed036

Updated: Feb 8, 2019

Last week we were lucky enough to have PhD student Shelby Newsad, from the University of Cambridge, present her research on the utility of algae within the modern world.


This multi-functional organism has great potential for use with pharmacology, as both a human and animal food source, for waste water treatment and as an energy source. This makes it an incredibly exciting future prospect for more eco-friendly, renewable solutions. Shelby’s work focuses mainly on the use of algae as a vitamin-enriched human food source. Requiring CO2 to grow, algae absorbs and replaces it with O2 producing clean air all whilst continuing to grow and ultimately provide a highly nutritious food source. With a complete amino acid profile it constitutes a complete protein, supporting various human metabolic processes and containing numerous minerals and nutrients. Shelby’s research and work for Alginity (a company focused on the use of algae as a nutritional source, backed by the European Space Agency) is hoping to fully harness the vast range of benefits of this food source in the coming years.


The use of Spirulina and Chlorella varieties of green algae have demonstrated antimicrobial, antioxidant and lipid-lowering activity allowing them to be used in pharmacological processes. As such it is certainly a product which will likely be influential within the field in the future.


Outside the pharma and health field, algae has brilliant potential as an environmentally-friendly alternative to wastewater treatment, energy sourcing and plastics. Microalgae culture is already being used as a tertiary bio treatment step for waste water treatment. Additionally, in terms of biofuel, algae can produce as much as 5,000 biofuel gallons from a single acre in one year, making it hugely economically viable. Single-use plastics are one of the most damaging products currently produced, resulting in huge efforts to find eco-friendly alternatives. Algae again provides an answer here, with companies using it to create “green plastics”.


Scientific research into the use of algae and other sustainable substances for everyday processes and essential tasks is sure to provide fascinating results in the near future and is certainly one to watch!


Fiona Williams


  • ahmed036

Updated: Dec 7, 2018

After conducting several projects in recent years in China, along with other emerging markets in Asia and Latin America, Access Infinity has made a conscious decision to need to dedicate some of our resources in the Far East. As with the expertise developed in EU5 and US markets, China has been a focus for many of our clients. It stands out as an attractive, unconventional and important market for several reasons:

  • Year on year growth in terms of per capita spending on healthcare currently stands at around $750.

  • A higher spending on pharmaceuticals in comparison to other developed markets makes it lucrative for pharmaceutical companies.

  • Whilst boasting free pricing, the reality of this market is one which employs a huge discounting strategy.

  • Pricing referencing among provinces at net prices makes it extremely challenging yet interesting to develop a launch sequence and provincial focus strategy.

  • There is huge disparity among different provinces in the healthcare benefits provided as well as affordability of its population.

  • It is one of very few countries which brings together Western Medication and Chinese Traditional Medication in the same mix of funding and treatment development.

  • There are approx. 70% western drugs and 30% Chinese medicines in the essential drug list of 520 products.

  • In the NRDL the distribution is nearing 50:50 (987 Chinese and 1140 Western medication)

Access Infinity aims to further develop its current expertise on China and work with several pharmaceutical companies in their pricing and market access strategies including conducting

1-1 payer research, advisory boards and discounting strategies. We have developed several local partnerships as well as dedicated resources in China to achieve this ambitious goal. As part of this endeavour, Access Infinity team members from global office in London and as well as its APAC office are spending a week there. China, here we come!


- Shrinivas Mukku.


London Head Office

Labs Atrium

The Stables Market

London

NW1 8AH

Social
Founding Director
  • LinkedIn - White Circle
  • Twitter - White Circle
  • Instagram - White Circle

Legal Policies